Keros Therapeutics, Inc. (KROS) Current Ratio
- Current ratio · latest quarter: Value 21.96×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 21.96× | Current assets / current liabilities. $266.88M ÷ $12.15M ≈ 21.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 266.88M USD | Assets, Current |
| Current obligations | 12.15M USD | Liabilities, Current |
| Cash and equivalents | 257.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 0.00 USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.82M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $266.88M | $12.15M | $257.61M | (m) | $0.00 | (m) | $1.82M | (m) | 21.96× |
| 2026-03-31 | $290.68M | $12.85M | $281.50M | (m) | $400.00K | (m) | $1.49M | (m) | 22.62× |
| 2025-12-31 | $315.43M | $20.41M | $287.42M | (m) | $3.57M | (m) | $1.97M | (m) | 15.45× |
| 2025-09-30 | $719.31M | $24.09M | $693.47M | (m) | $3.49M | (m) | $2.30M | (m) | 29.86× |
| 2025-06-30 | $732.81M | $34.71M | $690.22M | (m) | $15.82M | (m) | $5.27M | (m) | 21.11× |
| 2025-03-31 | $759.51M | $39.38M | $720.54M | (m) | $17.29M | (m) | $6.64M | (m) | 19.29× |
| 2024-12-31 | $588.89M | $27.45M | $559.93M | (m) | $2.74M | (m) | $4.60M | (m) | 21.45× |
| 2024-09-30 | $552.05M | $29.01M | $530.68M | (m) | $388.00K | (m) | $4.98M | (m) | 19.03× |
| 2024-06-30 | $432.71M | $21.25M | $405.86M | (m) | $4.00K | (m) | $6.54M | (m) | 20.37× |
| 2024-03-31 | $463.13M | $18.72M | $442.44M | (m) | $226.00K | (m) | $4.99M | (m) | 24.74× |
| 2023-12-31 | $347.29M | $24.37M | $331.15M | (m) | $143.00K | (m) | $5.45M | (m) | 14.25× |
| 2023-09-30 | $304.44M | $16.70M | $287.89M | (m) | (m) | (m) | $3.87M | (m) | 18.23× |
| 2023-06-30 | $334.31M | $16.09M | $322.03M | (m) | (m) | (m) | $4.15M | (m) | 20.77× |
| 2023-03-31 | $362.22M | $15.46M | $351.43M | (m) | (m) | (m) | $4.68M | (m) | 23.43× |
| 2022-12-31 | $285.77M | $16.55M | $279.05M | (m) | $0.00 | (m) | $3.34M | (m) | 17.27× |
| 2022-09-30 | $245.88M | $11.53M | $239.43M | (m) | $0.00 | (m) | $2.65M | (m) | 21.33× |
| 2022-06-30 | $222.36M | $15.45M | $215.62M | (m) | $0.00 | (m) | $7.66M | (m) | 14.39× |
| 2022-03-31 | $231.22M | $11.65M | $228.59M | (m) | $0.00 | (m) | $3.06M | (m) | 19.85× |
| 2021-12-31 | $251.44M | $11.85M | $230.04M | (m) | $18.00M | (m) | $3.65M | (m) | 21.23× |
| 2021-09-30 | $226.07M | $11.02M | $221.35M | (m) | (m) | (m) | $2.81M | (m) | 20.52× |
| 2021-06-30 | $241.42M | $7.53M | $237.11M | (m) | $100.00K | (m) | $1.37M | (m) | 32.06× |
| 2021-03-31 | $255.98M | $8.95M | $255.20M | (m) | (m) | (m) | $3.01M | (m) | 28.60× |
| 2020-12-31 | $267.73M | $7.18M | $265.88M | (m) | $0.00 | (m) | $2.15M | (m) | 37.27× |
| 2020-09-30 | $136.42M | $6.83M | $133.81M | (m) | (m) | (m) | $1.72M | (m) | 19.99× |
| 2020-06-30 | $148.52M | $8.29M | $144.69M | (m) | (m) | (m) | $4.85M | (m) | 17.91× |
| 2020-03-31 | $58.54M | $8.84M | $54.52M | (m) | (m) | (m) | $2.43M | (m) | 6.63× |
| 2019-12-31 | $8.93M | $4.49M | $7.02M | (m) | (m) | (m) | $2.09M | (m) | 1.99× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |